LEVERAGE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:00 04/06/2024 BST | ||
| 27.08 EUR | +12.60% |
|
| Current month | +26.14% | ||
| 1 month | +129.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 27.08 | +12.60% |
| 03/06/24 | 24.05 | +7.27% |
| 31/05/24 | 22.42 | -0.93% |
| 30/05/24 | 22.63 | +5.45% |
| 29/05/24 | 21.46 | -5.09% |
Real-time Euronext Paris
Last update June 04, 2024 at 05:30 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| SU58S | |
| ISIN | DE000SQ70QS4 |
| Date issued | 17/01/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5.09 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.45 € |
|---|---|
| Lowest since issue | 1.982 € |
| Spread | 4.02 € |
| Spread % | 13.79% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.3
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- SU58S Certificat
